Updated time: 2021-11-29 09:00:01
This invention relates to use of novel oncogenes, SLC29A2, especially its nuclear localization of SLC29A2 as a theranostic target.
Dipyridamole can inhibit the oncogenic mechanism of SLC29A2. Treating dipyridamole can significantly suppress the SLC29A2-expressing HCC progression and metastasis. Combination of dipyridamole and sorafenib can further suppress the tumor progression, metastasis, and prolong survival in orthotopic mic model.
- This invention relates to use of detecting SLC29A2 as theranostic marker. The aberrant expression of SLC29A2 is not only in HCC, but also in breast cancer, pancreatic cancer, and stomach cancer.
- Our results shows that the SLC29A2-expressing cells are resistant to sorafenib, and the combination treatment with dipyridamole can reduce the sorafenib resistant and improve the anti-cancer effect.
- Dipyridamole is a common clinical drug in cardiovascular medicine with almost no side effect. The results from our study shows that the inhibition effect of dipyridamole only shows on SLC29A2 highly-expressing cancer cells, but not the low-expressing cancer or normal cells. These results show that dipyridamole treatment for SLC29A2 expression patient is specific and safe.
12A-1050919
US 10912777 、TW I744444
The present invention relates generally to anti-cancer therapy, more specifically to treatment of SLC29A2 nuclear-expressing cancer cells in divergent cancer types.
Yuh-Shan Jou, Roger Shen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer cells